Literature DB >> 22090124

Respiratory syncytial virus glycoprotein G interacts with DC-SIGN and L-SIGN to activate ERK1 and ERK2.

Teresa R Johnson1, Jason S McLellan, Barney S Graham.   

Abstract

Respiratory syncytial virus (RSV) interaction with epithelial and dendritic cells (DCs) is known to require divalent cations, suggesting involvement of C-type lectins. RSV infection and maturation of primary human DCs are reduced in a dose-dependent manner by EDTA. Therefore, we asked whether RSV infection involves DC-SIGN (CD209) or its isoform L-SIGN (CD299) (DC-SIGN/R). Using surface plasmon resonance analysis, we demonstrated that the attachment G glycoprotein of RSV binds both DC- and L-SIGN. However, neutralization of DC- and L-SIGN on primary human DCs did not inhibit RSV infection, demonstrating that interactions between RSV G and DC- or L-SIGN are not required for productive infection. Thus, neither DC- nor L-SIGN represents a functional receptor for RSV. However, inhibition of these interactions increased DC activation, as evidenced by significantly higher levels of alpha interferon (IFN-α), MIP-1α, and MIP-1β in plasmacytoid DCs (pDCs) exposed to RSV after neutralization of DC-and L-SIGN. To understand the molecular interactions involved, intracellular signaling events triggered by purified RSV G glycoprotein were examined in DC- and L-SIGN-transfected 3T3 cells. RSV G interaction with DC- or L-SIGN was shown to stimulate ERK1 and ERK2 phosphorylation, with statistically significant increases relative to mock-infected cells. Neutralization of DC- and L-SIGN reduced ERK1/2 phosphorylation. With increased DC activation following DC- and L-SIGN neutralization and RSV exposure, these data demonstrate that the signaling events mediated by RSV G interactions with DC/L-SIGN are immunomodulatory and diminish DC activation, which may limit induction of RSV-specific immunity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22090124      PMCID: PMC3264376          DOI: 10.1128/JVI.06096-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  61 in total

1.  DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells.

Authors:  T B Geijtenbeek; D S Kwon; R Torensma; S J van Vliet; G C van Duijnhoven; J Middel; I L Cornelissen; H S Nottet; V N KewalRamani; D R Littman; C G Figdor; Y van Kooyk
Journal:  Cell       Date:  2000-03-03       Impact factor: 41.582

2.  Lung surfactant protein A provides a route of entry for respiratory syncytial virus into host cells.

Authors:  T P Hickling; R Malhotra; H Bright; W McDowell; E D Blair; R B Sim
Journal:  Viral Immunol       Date:  2000       Impact factor: 2.257

3.  Calcium requirement for syncytium formation in HEp-2 cells by respiratory syncytial virus.

Authors:  M S Shahrabadi; P W Lee
Journal:  J Clin Microbiol       Date:  1988-01       Impact factor: 5.948

4.  Surfactant protein A binds to the fusion glycoprotein of respiratory syncytial virus and neutralizes virion infectivity.

Authors:  R Ghildyal; C Hartley; A Varrasso; J Meanger; D R Voelker; E M Anders; J Mills
Journal:  J Infect Dis       Date:  1999-12       Impact factor: 5.226

5.  Identification of a linear heparin binding domain for human respiratory syncytial virus attachment glycoprotein G.

Authors:  S A Feldman; R M Hendry; J A Beeler
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

6.  Replication-dependent potent IFN-alpha induction in human plasmacytoid dendritic cells by a single-stranded RNA virus.

Authors:  Veit Hornung; Jörg Schlender; Margit Guenthner-Biller; Simon Rothenfusser; Stefan Endres; Karl-Klaus Conzelmann; Gunther Hartmann
Journal:  J Immunol       Date:  2004-11-15       Impact factor: 5.422

7.  CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus.

Authors:  Scott A Jeffers; Sonia M Tusell; Laura Gillim-Ross; Erin M Hemmila; Jenna E Achenbach; Gregory J Babcock; William D Thomas; Larissa B Thackray; Mark D Young; Robert J Mason; Donna M Ambrosino; David E Wentworth; James C Demartini; Kathryn V Holmes
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-20       Impact factor: 11.205

8.  The fusion glycoprotein of human respiratory syncytial virus facilitates virus attachment and infectivity via an interaction with cellular heparan sulfate.

Authors:  S A Feldman; S Audet; J A Beeler
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

9.  Iduronic acid-containing glycosaminoglycans on target cells are required for efficient respiratory syncytial virus infection.

Authors:  L K Hallak; P L Collins; W Knudson; M E Peeples
Journal:  Virology       Date:  2000-06-05       Impact factor: 3.616

10.  Infectious respiratory syncytial virus (RSV) effectively inhibits the proliferative T cell response to inactivated RSV in vitro.

Authors:  F M Preston; P L Beier; J H Pope
Journal:  J Infect Dis       Date:  1992-05       Impact factor: 5.226

View more
  49 in total

1.  CX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells.

Authors:  Tatiana Chirkova; Songbai Lin; Antonius G P Oomens; Kelsey A Gaston; Seyhan Boyoglu-Barnum; Jia Meng; Christopher C Stobart; Calvin U Cotton; Tina V Hartert; Martin L Moore; Assem G Ziady; Larry J Anderson
Journal:  J Gen Virol       Date:  2015-06-25       Impact factor: 3.891

2.  Design of a novel integration-deficient lentivector technology that incorporates genetic and posttranslational elements to target human dendritic cells.

Authors:  Semih U Tareen; Brenna Kelley-Clarke; Christopher J Nicolai; Linda A Cassiano; Lisa T Nelson; Megan M Slough; Chintan D Vin; Jared M Odegard; Derek D Sloan; Neal Van Hoeven; James M Allen; Thomas W Dubensky; Scott H Robbins
Journal:  Mol Ther       Date:  2013-12-06       Impact factor: 11.454

3.  Mutating the CX3C Motif in the G Protein Should Make a Live Respiratory Syncytial Virus Vaccine Safer and More Effective.

Authors:  S Boyoglu-Barnum; S O Todd; J Meng; T R Barnum; T Chirkova; L M Haynes; S J Jadhao; R A Tripp; A G Oomens; M L Moore; L J Anderson
Journal:  J Virol       Date:  2017-04-28       Impact factor: 5.103

4.  Presentation Modality of Glycoconjugates Modulates Dendritic Cell Phenotype.

Authors:  N A Hotaling; D M Ratner; R D Cummings; J E Babensee
Journal:  Biomater Sci       Date:  2014-10-01       Impact factor: 6.843

5.  Human Plasmacytoid Dendritic Cells Elicited Different Responses after Infection with Pathogenic and Nonpathogenic Junin Virus Strains.

Authors:  Soledad Negrotto; Hebe A Mena; Agustin E Ure; Carolina Jaquenod De Giusti; Mariela Bollati-Fogolín; Elba M Vermeulen; Mirta Schattner; Ricardo M Gómez
Journal:  J Virol       Date:  2015-04-29       Impact factor: 5.103

6.  Dendritic cell expression of the C-type lectin receptor CD209a: A novel innate parasite-sensing mechanism inducing Th17 cells that drive severe immunopathology in murine schistosome infection.

Authors:  Holly E Ponichtera; Miguel J Stadecker
Journal:  Exp Parasitol       Date:  2015-04-23       Impact factor: 2.011

7.  Prophylaxis with a respiratory syncytial virus (RSV) anti-G protein monoclonal antibody shifts the adaptive immune response to RSV rA2-line19F infection from Th2 to Th1 in BALB/c mice.

Authors:  Seyhan Boyoglu-Barnum; Tatiana Chirkova; Sean O Todd; Thomas R Barnum; Kelsey A Gaston; Patricia Jorquera; Lia M Haynes; Ralph A Tripp; Martin L Moore; Larry J Anderson
Journal:  J Virol       Date:  2014-07-02       Impact factor: 5.103

Review 8.  Structure and function of respiratory syncytial virus surface glycoproteins.

Authors:  Jason S McLellan; William C Ray; Mark E Peeples
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

9.  Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease.

Authors:  Peter L Collins; Rachel Fearns; Barney S Graham
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

10.  Molecular factors in dendritic cell responses to adsorbed glycoconjugates.

Authors:  Nathan A Hotaling; Richard D Cummings; Daniel M Ratner; Julia E Babensee
Journal:  Biomaterials       Date:  2014-04-16       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.